icon-folder.gif   Conference Reports for NATAP  
 
  EASL - The International Liver Congress 2014
49th Annual Meeting of the European
Association for the Study of the Liver
London, United Kingdom  April 9-13
Back grey_arrow_rt.gif
 
 
 
All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir With Or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study
 
 
  Reported by Jules Levin
EASL 2014 April 9-13 London, UK
 
Alessandra Mangia,1 Patrick Marcellin,2 Paul Kwo,3
Graham R. Foster,4 Maria Buti,5 Norbert Bräu,6 Andrew Muir,7
Jenny C. Yang,8 Hongmei Mo,8 Xiao Ding,8 Phil S. Pang,8
William T. Symonds,8 John G. McHutchison,8 Stefan Zeuzem,9 Nezam Afdhal10 1Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy; 2Centre Hospitalier Universitaire Beaujon, Clichy-sous-Bois, France; 3Indiana University School of Medicine, Indianapolis, IN, USA; 4Queen Mary's University of London, Barts Health, UK; 5Hospital Universitario Valle de Hebrón, Barcelona, Cataluña, Spain; 6Mount Sinai School of Medicine, New York, NY, USA; 7Duke University Medical Center, Durham, NC, USA; 8Gilead Sciences, Inc., Foster City, CA; 9Johann Wolfgang Goethe University, Frankfurt, Germany; 10Beth Israel Deaconess Medical Center, Boston, MA, USA

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif

EASL11.gif

EASL12.gif